Moreover, approximately 10% of cases of BPDCN have IDH2 hotspot mutations, which typically occur in cases with wild-type TET2 and cause TET2 inhibition through the 2-HG oncometabolite12,17,23–25. Here, TET2 is linked to CD4+/CD56+ hematodermic neoplasm.